Physician profile
Palashkumar Jaiswal
NPI 1184004301
$5,962.39
in general payments reported to CMS, 2019-2025
34 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $65.01 · 2021: $29.64 · 2022: $1,211 · 2023: $1,760 · 2024: $1,712 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,491 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,491.37 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,009.47 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $442.85 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $397.97 | 2022-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $329.08 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Abbott Laboratories | $268.85 | 2023-2024 | Freestyle Libre 3 |
| Genzyme Corporation | $261.84 | 2022-2025 | |
| Qol Medical, LLC | $226.84 | 2022-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $181.36 | 2022-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $171.42 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $152.99 | 2022-2025 | Linzess |
| Dova Pharmaceuticals | $143.05 | 2019 | |
| Aimmune Therapeutics, INC. | $130.88 | 2024-2025 | Zenpep |
| Celgene Corporation | $109.86 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $105.38 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $102.99 | 2022-2023 | Ocaliva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $95.01 | 2024 | Omnipod |
| Novo Nordisk INC | $88.31 | 2024-2025 | Wegovy |
| Lilly USA, LLC | $86.90 | 2024 | Omvoh |
| Bayer Healthcare Pharmaceuticals INC. | $85.34 | 2023 | |
| Gilead Sciences, INC. | $70.33 | 2020-2024 | |
| Ardelyx, INC. | $69.55 | 2023-2024 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $62.31 | 2024 | Bylvay, Iqirvo |
| Pfizer INC. | $56.73 | 2023-2024 | |
| Boston Scientific Corporation | $45.38 | 2025 | Cre Pro, Captivator II |
| Phathom Pharmaceuticals, INC. | $44.71 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $44.05 | 2023 | Smoflipid |
| Ferring Pharmaceuticals INC. | $34.61 | 2022-2023 | Rebyota |
| Madrigal Pharmaceuticals | $33.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $29.05 | 2024-2025 | Vegzelma |
| Amgen INC. | $21.92 | 2023 | Amjevita, Avsola |
| E.R. Squibb & Sons, L.L.C. | $19.49 | 2022 | |
| Pentax of America, INC. | $16.32 | 2020 | |
| Organon LLC | $14.70 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $9.43 | 2023 | Dat Closure Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Palashkumar Jaiswal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.